Is tumor progression-related transmembrane protein aspartate-β-hydroxylase a target for immunotherapy of hepatocellular carcinoma?
Immunization with ASPH-loaded DCs has substantial anti-tumor effects which could reduce the risk of HCC recurrence.
In MG, E-C coupling appears to be impaired, particularly in patients with thymoma, and FK506 possibly facilitates E-C coupling.